Proinflammatory Cytokines, Immune Response and Tumour Progression

  1. Derek J. Chadwick Organizer,
  2. Jamie A. Goode
  1. Michela Spadaro,
  2. Guido Forni*

Published Online: 7 OCT 2008

DOI: 10.1002/0470856734.ch7

Cancer and Inflammation: Novartis Foundation Symposium 256

Cancer and Inflammation: Novartis Foundation Symposium 256

How to Cite

Spadaro, M. and Forni, G. (2008) Proinflammatory Cytokines, Immune Response and Tumour Progression, in Cancer and Inflammation: Novartis Foundation Symposium 256 (eds D. J. Chadwick and J. A. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470856734.ch7

Author Information

  1. Department of Clinical and Biological Sciences, University of Torino, Ospedale San Luigi Gonzaga, 10043 Orbassano, Italy

*Department of Clinical and Biological Sciences, University of Torino, Ospedale San Luigi Gonzaga, 10043 Orbassano, Italy

Publication History

  1. Published Online: 7 OCT 2008
  2. Published Print: 23 JAN 2004

Book Series:

  1. Novartis Foundation Symposia

Book Series Editors:

  1. Novartis Foundation

ISBN Information

Print ISBN: 9780470855102

Online ISBN: 9780470856734

SEARCH

Summary

Tumour cells naturally secrete proinflammatory cytokines and chemokines to interact with the microenvironment and regulate neoangiogenesis. The repertoire of factors thus produced shapes tumour progression. However, experiments in the mouse have shown that injection of a low pharmacological dose of a proinflammatory cytokine or chemokine into the microenvironment increases the inflammatory reaction so enormously that locally activated leukocytes inhibit or eradicate the tumour. Massive shrinkage of recurrent head and neck squamous cell carcinomas (SCC) and prevention of recurrences after surgical removal of a primary SCC follow perilymphatic administration of low doses of interleukin (IL)2, while low daily doses of IL12 markedly delay carcinogenesis in transgenic mice predestined to die of mammary carcinomas and keep them tumour-free for long periods. The reaction elicited by proinflammatory cytokines evidently has a great potential in tumour control.